91641-02-0

Usage

Chemical classification

1,2,3,4-Tetrahydroquinolinepropionic acid is a chemical compound that is a derivative of quinoline and a propionic acid.

Molecular structure

It has a molecular structure that is similar to that of the neurotransmitter dopamine.

Pharmaceutical applications

It has potential pharmaceutical applications, as it has been studied for its potential as an anti-inflammatory and analgesic agent.

Preclinical research

It has shown promise in preclinical research for its ability to reduce pain and inflammation.

Neuroprotective effects

It has also been investigated for its potential neuroprotective effects and as a potential treatment for neurodegenerative diseases.

Further research needed

Further research is needed to fully understand the potential therapeutic applications of 1,2,3,4-tetrahydroquinolinepropionic acid and its derivatives.

Type of compound

It is a chemical compound with potential pharmaceutical applications.

Main uses

It has been studied for its potential as an anti-inflammatory and analgesic agent, and for its potential neuroprotective effects and as a potential treatment for neurodegenerative diseases.

Current status

It is not yet fully understood and requires further research to determine its potential therapeutic applications.

InChI:InChI=1/C12H15NO2/c14-12(15)7-9-13-8-3-5-10-4-1-2-6-11(10)13/h1-2,4,6H,3,5,7-9H2,(H,14,15)

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 3395-91-3 Methyl 3-bromopropionate 
• 292638-85-8 acrylic acid methyl ester 
• 2637-29-8 N-(β-cyanoethyl)-1,2,3,4-tetrahydroquinoline 

Downstream Products

• 51315-09-4 julolidin-1-one 
• 500870-15-5 5,6-dihydro-4H,8H-benzo[b]quino[1,8-gh][1,6]naphthyridine-9-carboxylic acid 
• 7093-26-7 5,6,8,14-tetrahydro-4H-benzo[b]quino[1,8-gh][1,6]naphthyridinylium betaine 
• 1051934-79-2 C₁₈H₂₀N₂O 

Relevant academic research and scientific papers

The optimization of a novel selective antagonist for human M2 muscarinic acetylcholine receptor

Muscarinic acetylcholine receptors (mAChRs) comprise five distinct subtypes denoted M1 to M5. The antagonism of M2 subtype could increase the release of acetylcholine from vesicles into the synaptic cleft and improve postsynaptic functions in the hippocampus via M1 receptor activation, displaying therapeutic potentials for Alzheimer's disease. However, drug development for M2 antagonists is still challenged among different receptor subtypes. In this study, by optimizing a scaffold from virtual screening, we synthesized two focused libraries and generated up to 50 derivatives. By measuring potency and binding selectivity, we discovered a novel M2 antagonist, ligand 47, featuring submicromolar IC50, high M2/M4 selectivity (~30-fold) and suitable lipophilicity (cLogP = 4.55). Further study with these compounds also illustrates the structure–activity relationship of this novel scaffold. Our study could not only provide novel lead structure, which was easy to synthesize, but also offer valuable information for further development of selective M2 ligands.

Autophagy and phospholipidosis pathway assays

Provided are assays useful for detecting and monitoring autophagy and phospholipidosis, including the progression of lysosomal storage diseases. Drugs and treatments for lysosomal storage diseases can be monitored for effectiveness in lysosomal storage disease conditions. Drug candidates and suspected toxic agents can also be screened for toxicity to cells, tissues and organs. Also provided are methods for distinguishing between phospholipidosis activators and autophagy pathway perturbation agents.

Microbiological Transformations, Part 9. Microbiological Transformations of 1,2,5,6-Tetrahydropyrroloquinolin-4-one and of Derivatives of 1,2,3,5,6,7-Hexahydropyridoquinoline with the Fungus Cunninghamella elegans

Incubation of 1,2,6,7-tetrahydropyridoquinolin-3(5H)-one with C. elegans resulted in oxidation at the C-7 benzylic position, whereas 1-methyl-1,2,6,7-tetrahydropyridoquinolin-5(3H)-one gave products resulting from oxidation at both benzylic positions. cis- and trans-1-Hydroxy-3-methyl-1,2,6,7-tetrahydropyridoquinolin-5(3H)-ones were produced on incubation of 5-methyl-1,2,6,7-tetrahydropyridoquinolin-3(5H)-one with C. elegans, in addition to trans-1-hydroxy-5-methyl-1,2,6,7-tetrahydropyridoquinolin-3(5H)-one.Incubation of 1,2,5,6-tetrahydropyrroloquinolin-4-one with C. elegans resulted in dehydrogenation to 1,2-dihydropyrroloquinolin-4-one.Incubation of 2,3,6,7-tetrahydropyridoquinolin-1(5H)-one with C. elegans resulted in benzylic attack at C-7.